Article: Should metformin remain the first-line therapy for treatment of type 2 diabetes?
Therapeutic advances in endocrinology and metabolism
2021 Volume 12, Page(s) 2042018820980225
Abstract: Metformin is a biguanide that is used as first-line treatment of type 2 diabetes mellitus and is effective as monotherapy and in combination with other glucose-lowering medications. It is generally well-tolerated with minimal side effects and is ... ...
| Abstract | Metformin is a biguanide that is used as first-line treatment of type 2 diabetes mellitus and is effective as monotherapy and in combination with other glucose-lowering medications. It is generally well-tolerated with minimal side effects and is affordable. Although the safety and efficacy of metformin have been well-established, there is discussion regarding whether metformin should continue to be the first choice for therapy as other anti-hyperglycemic medications exhibit additional advantages in certain populations. Despite a long-standing history of metformin use, there are limited cardiovascular outcomes data for metformin. Furthermore, the available studies fail to provide strong evidence due to either small sample size or short duration. Recent data from glucagon-like peptide-1 receptor agonist and sodium-glucose cotransporter-2 inhibitor cardiovascular and renal outcomes trials demonstrated additional protection from diabetes complications for some high-risk patients, which has impacted the guidelines for diabetes management. Post-hoc analyses comparing hazard ratios for participants taking metformin at baseline |
|---|---|
| Language | English |
| Publishing date | 2021-01-13 |
| Publishing country | United States |
| Document type | Journal Article ; Review |
| ZDB-ID | 2554822-0 |
| ISSN | 2042-0196 ; 2042-0188 |
| ISSN (online) | 2042-0196 |
| ISSN | 2042-0188 |
| DOI | 10.1177/2042018820980225 |
| Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.